RT Journal
A1 Moroi SE
T1 EYelash preservation during chemotherapy and topical prostaglandin therapy
JF Archives of Internal Medicine
JO Archives of Internal Medicine
YR 2010
FD July 26
VO 170
IS 14
SP 1269
OP 1270
DO 10.1001/archinternmed.2010.247
UL http://dx.doi.org/10.1001/archinternmed.2010.247
AB 
Hair loss is a common adverse effect of chemotherapy and has an impact on self-image. It may include loss of eyelashes, which trap particulate matter from the ocular surface. There is evidence that topical prostaglandins induce ocular hair growth.1 Their effect on eyelash prominence is further highlighted by the recent approval of the prostaglandin analog bimatoprost, 0.03% (Allergan Inc, Irvine, California), by the Food and Drug Administration for treatment of hypotrichosis of eyelashes. Herein, I describe a patient who was treated with a topical prostaglandin and retained eyelashes during chemotherapy treatment for breast cancer.